This site is intended for U.S. residents only.

Learn about treatment with KYPROLIS® (carfilzomib)

Here you can find information about the dosing, administration, and treatment schedule with KYPROLIS®. You can also access a tracker that can help you prepare for your KYPROLIS® treatment.

How is KYPROLIS® given?

KYPROLIS® is given as an infusion in your doctor's office, a clinic, or a hospital. That means you will receive medicine through an IV, directly into a vein.

Treatment is given on a schedule of 4 weeks. Each 4-week schedule is called a treatment cycle.

KYPROLIS® can be given in combination with other medicines (combination therapy) or by itself (monotherapy). Your doctor will prescribe one of the treatment plans listed below.

Select one of the treatment plans below to understand the schedule and plan ahead for your KYPROLIS® treatment.

KYPROLIS®, given with Revlimid® and dexamethasone +

KYPROLIS® can be given with other treatments. One combination is with Revlimid and dexamethasone.

Revlimid is taken as a pill, so you'll be able to take it at home. Dexamethasone can be given as an infusion or taken as a pill. You'll get it 30 minutes to 4 hours before your KYPROLIS® infusion.

Here is what your schedule may look like for your first 12 treatment cycles:

Cycles 1-12
KYPROLIS® Asset 1 Asset 2

You may receive KYPROLIS® 2 days in a row for the first 3 weeks of each treatment cycle.*

You should not have an infusion of KYPROLIS® during the fourth week.

Revlimid Asset 1 Asset 2

You should take Revlimid once daily for the first 3 weeks of each treatment cycle.

dexamethasone Asset 1 Asset 2

You should get dexamethasone on the first day of each week for all 4 weeks.

On days when you receive both KYPROLIS® and dexamethasone, you should receive dexamethasone 30 minutes to 4 hours before your KYPROLIS® infusion.

Your doctor may prescribe KYPROLIS® differently, which could change your treatment schedule. Talk to your doctor about the treatment plan that's right for you.

*Your doctor should give you a lower dose during the first week of your first treatment cycle. If you tolerate that dose, your doctor may increase the dose of your other infusions of KYPROLIS®. Your doctor will determine the right dose for you.

After your first 12 treatment cycles, your doctor may adjust how often you receive KYPROLIS®. You will receive KYPROLIS® through Cycle 18. After Cycle 18, you will receive only Revlimid and dexamethasone.

Cycles 13 and later
KYPROLIS® Asset 1 Asset 2

You may receive KYPROLIS® 2 days in a row on the first and third weeks of each treatment cycle.

You should not have an infusion of KYPROLIS® during the second and fourth weeks.

Revlimid Asset 1 Asset 2

You should continue to take Revlimid once daily for the first 3 weeks of each treatment cycle.

dexamethasone Asset 1 Asset 2

You should also continue to get dexamethasone on the first day of each week for all 4 weeks.

On days when you receive both KYPROLIS® and dexamethasone, you should receive dexamethasone 30 minutes to 4 hours before your KYPROLIS® infusion.

KYPROLIS®, given with dexamethasone +

KYPROLIS® can be given with other treatments. One combination is with dexamethasone, a medicine that can be given as an infusion or taken as a pill.

KYPROLIS® and dexamethasone can be given in 2 ways: on a once-weekly schedule at a higher dose or on a twice-weekly schedule at a lower dose.

Here is what your schedule may look like if you receive KYPROLIS® once a week:

Cycles 1-9
KYPROLIS® Asset 3 Asset 3

You may receive KYPROLIS® on the same day of the week for the first 3 weeks of each treatment cycle.*

You should not have an infusion of KYPROLIS® during the fourth week.

dexamethasone Asset 3 Asset 3

You should get dexamethasone on the same day you get KYPROLIS® each week. You will also get dexamethasone on that day in the fourth week, even though you will not receive KYPROLIS®.

On days when you receive both KYPROLIS® and dexamethasone, you should receive dexamethasone 30 minutes to 4 hours before your KYPROLIS® infusion.

Your doctor may prescribe KYPROLIS® differently, which could change your treatment schedule. Talk to your doctor about the treatment plan that's right for you.

After your first 9 treatment cycles, your doctor may adjust how often you receive dexamethasone.

Cycles 10 and later
KYPROLIS® Asset 3 Asset 3

You should continue to receive KYPROLIS® on the same day of the week for the first 3 weeks of each treatment cycle.

You should not have an infusion of KYPROLIS® during the fourth week.

dexamethasone Asset 3 Asset 3

You should continue to get dexamethasone on the same day you get KYPROLIS® each week. You will not get dexamethasone during the fourth week.

On days when you receive both KYPROLIS® and dexamethasone, you should receive dexamethasone 30 minutes to 4 hours before your KYPROLIS® infusion.


Here is what your schedule may look like if you receive KYPROLIS® twice a week:

All treatment cycles
KYPROLIS® Asset 3 Asset 3

You may receive KYPROLIS® 2 days in a row for the first 3 weeks of each treatment cycle.*

You should not have an infusion of KYPROLIS® during the fourth week.

dexamethasone Asset 3 Asset 3

You should get dexamethasone on the days you get KYPROLIS®. You will also get dexamethasone during the fourth week, even though you will not receive KYPROLIS®.

On days when you receive both KYPROLIS® and dexamethasone, you should receive dexamethasone 30 minutes to 4 hours before your KYPROLIS® infusion.

Your doctor may prescribe KYPROLIS® differently, which could change your treatment schedule. Talk to your doctor about the treatment plan that's right for you.

*Your doctor should give you a lower dose during the first week of your first treatment cycle. If you tolerate that dose, your doctor may increase the dose of your other infusions of KYPROLIS®. Your doctor will determine the right dose for you.

KYPROLIS®, given alone +

KYPROLIS® can also be given alone.

Here is what your schedule may look like if you receive KYPROLIS® as monotherapy:

Cycles 1-12
KYPROLIS® Asset 3 Asset 3

You may receive KYPROLIS® 2 days in a row for the first 3 weeks of each treatment cycle.*

You should not have an infusion of KYPROLIS® during the fourth week.

Cycles 13 and later
KYPROLIS® Asset 3 Asset 3

You may receive KYPROLIS® 2 days in a row on the first and third weeks of each treatment cycle.

You should not have an infusion of KYPROLIS® during the second and fourth weeks.

You may also take another medicine called dexamethasone during your first treatment cycle. Dexamethasone can be given as an infusion or taken as a pill, and you'll get it 30 minutes to 4 hours before each of your KYPROLIS® infusions.

Your doctor may prescribe KYPROLIS® differently, which could change your treatment schedule. Talk to your doctor about the treatment plan that's right for you.

*Your doctor should give you a lower dose during the first week of your first treatment cycle. If you tolerate that dose, your doctor may increase the dose of your other infusions of KYPROLIS®. Your doctor will determine the right dose for you.

Talk to your doctor about the right treatment plan for you.

If your doctor has prescribed KYPROLIS® for you, ask about the KYPROLIS® Starter Kit. It has useful tools to help you take an active role in your care. Find resources to help you start treatment.

Discover how Amgen Assist 360™ can help you find resources most important to you.
Call 888-4ASSIST (888-427-7478) Monday through Friday, 9 am to 8 pm Eastern Time.

*Terms in burgundy can be found in the Glossary.

^Back to top

IMPORTANT SAFETY INFORMATION

KYPROLIS® (carfilzomib) can cause serious side effects:
  • Heart problems: KYPROLIS can cause heart problems or worsen pre-existing heart conditions. Death due to cardiac arrest has occurred within one day of KYPROLIS administration. Before starting KYPROLIS, you should have a full medical work-up (including blood pressure and fluid management). You should be closely monitored during treatment.
  • Kidney problems: There have been reports of sudden kidney failure in patients receiving KYPROLIS. Your kidney function should be closely monitored during treatment.
  • Tumor lysis syndrome (TLS): Cases of TLS have been reported in patients receiving KYPROLIS, including fatalities. You should be closely monitored during treatment for any signs of TLS.
  • Lung damage: Cases of lung damage have been reported in patients receiving KYPROLIS, including fatal cases.
  • Pulmonary hypertension (high blood pressure in the lungs): There have been reports of pulmonary hypertension in patients receiving KYPROLIS.
  • Lung complications: Shortness of breath was reported in patients receiving KYPROLIS. Your lung function should be closely monitored during treatment.
  • High blood pressure: Cases of high blood pressure, including fatal cases, have been reported in patients receiving KYPROLIS. Your blood pressure should be closely monitored during treatment.
  • Blood clots: There have been reports of blood clots in patients receiving KYPROLIS. If you are at high risk for blood clots, your doctor can recommend ways to lower the risk.
  • If you are using KYPROLIS in combination with dexamethasone or with lenalidomide plus dexamethasone, your doctor should assess and may prescribe another medicine to help lower your risk for blood clots.
  • If you are using birth control pills or other medical forms of birth control associated with a risk of blood clots, talk to your doctor and consider a different method of birth control during treatment with KYPROLIS in combination with dexamethasone or with lenalidomide plus dexamethasone.
  • Infusion reactions: Symptoms of infusion reactions included fever, chills, joint pain, muscle pain, facial flushing and/or swelling, vomiting, weakness, shortness of breath, low blood pressure, fainting, chest tightness, and chest pain. These symptoms can occur immediately following infusion or up to 24 hours after administration of KYPROLIS. If you experience any of these symptoms, contact your doctor immediately.
  • Severe bleeding problems: Fatal or serious cases of bleeding problems have been reported in patients receiving KYPROLIS. Your doctor should monitor your signs and symptoms of blood loss.
  • Very low platelet count: Low platelet levels can cause unusual bruising and bleeding. You should have regular blood tests to check your platelet count during treatment.
  • Liver problems: Cases of liver failure, including fatal cases, have been reported in patients receiving KYPROLIS. Your liver function should be closely monitored during treatment.
  • Blood problems: Cases of a blood disease called thrombotic microangiopathy, including thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS), including fatal cases, have been reported in patients who received KYPROLIS. Your doctor should monitor your signs and symptoms.
  • Brain problems: A nerve disease called Posterior Reversible Encephalopathy Syndrome (PRES), formerly called Reversible Posterior Leukoencephalopathy Syndrome (RPLS), has been reported in patients receiving KYPROLIS. It can cause seizure, headache, lack of energy, confusion, blindness, altered consciousness, and other visual and nerve disturbances, along with high blood pressure. Your doctor should monitor your signs and symptoms.
  • KYPROLIS should not be combined with melphalan and prednisone: Newly diagnosed transplant ineligible multiple myeloma patients have shown an increased risk of serious and fatal side effects when using KYPROLIS in combination with melphalan and prednisone.
  • Possible fetal harm: KYPROLIS can cause harm to a fetus (unborn baby) when given to a pregnant woman. Women should avoid becoming pregnant during treatment with KYPROLIS and for 6 months following the final dose. Men should avoid fathering a child during treatment with KYPROLIS and for 3 months following the final dose. KYPROLIS can cause harm to a fetus if used during pregnancy or if you or your partner become pregnant during treatment with KYPROLIS.
You should contact your doctor immediately if you experience any of the following:
  • Shortness of breath
  • Prolonged, unusual or excessive bleeding
  • Yellowing of the skin and/or eyes (jaundice)
  • Headaches, confusion, seizures, or loss of sight
  • Pregnancy (women should not receive KYPROLIS if they are pregnant or breastfeeding)
  • Any other side effect that bothers you or does not go away
What are the possible side effects of KYPROLIS?
  • The most common side effects occurring in at least 20% of patients receiving KYPROLIS in the combination therapy trials are: low red blood cell count, low white blood cell count, diarrhea, difficulty breathing, tiredness (fatigue), low platelets, fever, sleeplessness (insomnia), muscle spasm, cough, upper airway (respiratory tract) infection, and decreased potassium levels.
  • The most common side effects occurring in at least 20% of patients receiving KYPROLIS when used alone (monotherapy) in trials are: low red blood cell count, tiredness (fatigue), low platelets, nausea, fever, difficulty breathing, diarrhea, headache, cough, swelling of the lower legs or hands.

These are not all the possible side effects of KYPROLIS. For more information, ask your doctor or pharmacist. Call your doctor for medical advice about side effects.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see full Product Information.

APPROVED USES

  • KYPROLIS® (carfilzomib) is a prescription medication used to treat patients with relapsed or refractory multiple myeloma who have received one to three previous treatments for multiple myeloma. KYPROLIS is approved for use in combination with dexamethasone or with lenalidomide plus dexamethasone, which are other medicines used to treat multiple myeloma.
  • KYPROLIS® is a prescription medication used to treat patients with relapsed or refractory multiple myeloma who have received one or more previous treatments for multiple myeloma. KYPROLIS is approved for use alone to treat relapsed or refractory multiple myeloma.